Aldeyra Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: ALDX · Form: 8-K · Filed: Jun 11, 2025 · CIK: 1341235
| Field | Detail |
|---|---|
| Company | Aldeyra Therapeutics, INC. (ALDX) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: ALDX
TL;DR
Aldeyra Therapeutics had a shareholder vote on June 10th, details to follow.
AI Summary
Aldeyra Therapeutics, Inc. filed an 8-K on June 11, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 10, 2025. The filing does not provide details on the specific matters voted upon or the outcome.
Why It Matters
This filing indicates that Aldeyra Therapeutics held a vote of its security holders, which could pertain to significant corporate actions or governance changes that may impact shareholders.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any new financial or operational risks.
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- June 11, 2025 (date) — Filing Date
- June 10, 2025 (date) — Date of Earliest Event Reported
- Lexington, MA (location) — Principal Executive Offices
FAQ
What specific matters were submitted for a vote of Aldeyra Therapeutics' security holders on June 10, 2025?
The filing does not specify the exact matters submitted for a vote.
What was the outcome of the vote by Aldeyra Therapeutics' security holders on June 10, 2025?
The filing does not disclose the results or outcome of the vote.
When was this 8-K filing submitted to the SEC?
The filing was submitted on June 11, 2025.
What is the principal executive office address for Aldeyra Therapeutics?
The principal executive offices are located at 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
What is Aldeyra Therapeutics' standard industrial classification?
The company's standard industrial classification is Pharmaceutical Preparations [2834].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 11, 2025 regarding Aldeyra Therapeutics, Inc. (ALDX).